Literature DB >> 28749012

Disulfide Bond Mimetics: Strategies and Challenges.

Alessandro Gori1, Paola Gagni1, Silvia Rinaldi1.   

Abstract

The activity profile of many biologically relevant proteins and peptides often relies on a precise 3D structural organization. In this context, disulfide bonds are natural covalent constraints that play a key role in driving and stabilizing the folding pattern of these molecules. Despite its prominent significance as structural motif, the disulfide bond itself is inherently unstable under physiological conditions, posing a major limit to the use and development of disulfide-rich peptides and proteins as molecular tools and drug lead compounds. To tackle this restriction, disulfide engineering with stable functional analogues has arisen a considerable interest. Here, the most popular approaches to disulfide replacement are reviewed and discussed with particular emphasis on advantages and limitations under both functional and synthetic perspectives.
© 2017 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  cyclic peptides; disulfide isosters; drug discovery; peptidomimetics; protein folding

Year:  2017        PMID: 28749012     DOI: 10.1002/chem.201703199

Source DB:  PubMed          Journal:  Chemistry        ISSN: 0947-6539            Impact factor:   5.236


  9 in total

1.  Synthesis and Characterization of an A6-A11 Methylene Thioacetal Human Insulin Analogue with Enhanced Stability.

Authors:  Nan Zheng; Prasoona Karra; Michael A VandenBerg; Jin Hwan Kim; Matthew J Webber; William L Holland; Danny Hung-Chieh Chou
Journal:  J Med Chem       Date:  2019-12-13       Impact factor: 7.446

2.  Heterogeneous-Backbone Foldamer Mimics of a Computationally Designed, Disulfide-Rich Miniprotein.

Authors:  Chino C Cabalteja; Daniel S Mihalko; W Seth Horne
Journal:  Chembiochem       Date:  2018-11-27       Impact factor: 3.164

3.  Development of Conformationally Constrained α-RgIA Analogues as Stable Peptide Antagonists of Human α9α10 Nicotinic Acetylcholine Receptors.

Authors:  Nan Zheng; Sean B Christensen; Alan Blakely; Cheryl Dowell; Landa Purushottam; J Michael McIntosh; Danny Hung-Chieh Chou
Journal:  J Med Chem       Date:  2020-07-16       Impact factor: 8.039

Review 4.  A Patent Review on SARS Coronavirus Main Protease (3CLpro ) Inhibitors.

Authors:  C S Brian Chia; Weijun Xu; Pearly Shuyi Ng
Journal:  ChemMedChem       Date:  2021-10-28       Impact factor: 3.540

Review 5.  Potentials of Neuropeptides as Therapeutic Agents for Neurological Diseases.

Authors:  Xin Yi Yeo; Grace Cunliffe; Roger C Ho; Su Seong Lee; Sangyong Jung
Journal:  Biomedicines       Date:  2022-02-01

6.  De novo design and directed folding of disulfide-bridged peptide heterodimers.

Authors:  Sicong Yao; Adam Moyer; Yiwu Zheng; Yang Shen; Xiaoting Meng; Chong Yuan; Yibing Zhao; Hongwei Yao; David Baker; Chuanliu Wu
Journal:  Nat Commun       Date:  2022-03-22       Impact factor: 17.694

7.  Directed Evolution-Driven Increase of Structural Plasticity Is a Prerequisite for Binding the Complement Lectin Pathway Blocking MASP-Inhibitor Peptides.

Authors:  Zsolt Dürvanger; Eszter Boros; Zoltán Attila Nagy; Rózsa Hegedüs; Márton Megyeri; József Dobó; Péter Gál; Gitta Schlosser; Annamária F Ángyán; Zoltán Gáspári; András Perczel; Veronika Harmat; Gábor Mező; Dóra K Menyhárd; Gábor Pál
Journal:  ACS Chem Biol       Date:  2022-04-04       Impact factor: 4.634

8.  Discovery of Methylene Thioacetal-Incorporated α-RgIA Analogues as Potent and Stable Antagonists of the Human α9α10 Nicotinic Acetylcholine Receptor for the Treatment of Neuropathic Pain.

Authors:  Nan Zheng; Sean B Christensen; Cheryl Dowell; Landa Purushottam; Jack J Skalicky; J Michael McIntosh; Danny Hung-Chieh Chou
Journal:  J Med Chem       Date:  2021-06-23       Impact factor: 7.446

Review 9.  α-Conotoxin Peptidomimetics: Probing the Minimal Binding Motif for Effective Analgesia.

Authors:  Adam C Kennedy; Alessia Belgi; Benjamin W Husselbee; David Spanswick; Raymond S Norton; Andrea J Robinson
Journal:  Toxins (Basel)       Date:  2020-08-06       Impact factor: 4.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.